Bull Case

Commercial adoption of Nyxoah’s Genio system accelerates in the U.S. and Europe, lifting procedure volumes and revenue growth versus smaller sleep-apnea peers.

Broader reimbursement coverage and stronger physician conversion improve utilization, allowing fixed operating costs to absorb faster than peers and narrowing losses.

Manufacturing and supply-chain execution stabilize, reducing gross-to-operating cost leakage and supporting margin expansion from a currently negative operating margin base.

Balance-sheet pressure remains manageable because net debt is low, giving Nyxoah more runway than highly leveraged medtech peers to fund commercialization.

Base Case

U.S. launch progress and European sales growth continue, but adoption remains gradual, keeping revenue expansion ahead of niche peers yet below scaled medtech competitors.

Reimbursement and clinical evidence improve incrementally, supporting steady but uneven procedure growth and limiting the pace of operating leverage.

Operating losses persist as commercialization spending stays elevated, so margins improve only modestly from the current negative level rather than turning positive quickly.

Low leverage reduces financing risk versus debt-heavy peers, but weak interest coverage and negative cash generation keep valuation and execution constrained.

Bear Case

U.S. commercialization underperforms and reimbursement progress stalls, causing procedure growth to lag direct sleep-apnea peers and delaying revenue scale.

Competitive alternatives and slower physician adoption pressure conversion rates, leaving operating expenses underutilized and extending negative margins.

Cash burn remains elevated while interest coverage stays negative, increasing financing risk despite relatively low net debt versus more leveraged peers.

If execution slips further, the company could lose relative momentum to better-capitalized medtech peers, forcing slower expansion and weaker operating flexibility.

Overall Score

NYXH’s forward profile is supported by low leverage and commercialization upside, but persistent losses and execution risk keep the most probable outcome only moderately favorable versus peers.